Literature DB >> 20008785

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Francesco Passamonti1, Francisco Cervantes, Alessandro Maria Vannucchi, Enrica Morra, Elisa Rumi, Arturo Pereira, Paola Guglielmelli, Ester Pungolino, Marianna Caramella, Margherita Maffioli, Cristiana Pascutto, Mario Lazzarino, Mario Cazzola, Ayalew Tefferi.   

Abstract

Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 x 10(9)/L, peripheral blood blasts 1% or higher, and constitutional symptoms have been shown to predict poor survival in primary myelofibrosis (PMF) at diagnosis. To investigate whether the acquisition of these factors during follow-up predicts survival, we studied 525 PMF patients regularly followed. All 5 variables had a significant impact on survival when analyzed as time-dependent covariates in a multivariate Cox proportional hazard model and were included in 2 separate models, 1 for all patients (Dynamic International Prognostic Scoring System [DIPSS]) and 1 for patients younger than 65 years (age-adjusted DIPSS). Risk factors were assigned score values based on hazard ratios (HRs). Risk categories were low, intermediate-1, intermediate-2, and high in both models. Survival was estimated by the HR. When shifting to the next risk category, the HR was 4.13 for low risk, 4.61 for intermediate-1, and 2.54 for intermediate-2 according to DIPSS; 3.97 for low risk, 2.84 for intermediate-1, and 1.81 for intermediate-2 according to the age-adjusted DIPSS. The novelty of these models is the prognostic assessment of patients with PMF anytime during their clinical course, which may be useful for treatment decision-making.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008785     DOI: 10.1182/blood-2009-09-245837

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  267 in total

1.  Prognostication in primary myelofibrosis.

Authors:  Francisco Cervantes; Arturo Pereira
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.

Authors:  O Abdel-Wahab; A Pardanani; R Rampal; T L Lasho; R L Levine; A Tefferi
Journal:  Leukemia       Date:  2011-04-26       Impact factor: 11.528

3.  Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Authors:  Markus Ditschkowski; Ahmet H Elmaagacli; Rudolf Trenschel; Tanja Gromke; Nina K Steckel; Michael Koldehoff; Dietrich W Beelen
Journal:  Haematologica       Date:  2012-04-04       Impact factor: 9.941

4.  Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis.

Authors:  Animesh Pardanani; Ayalew Tefferi
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

Review 5.  Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.

Authors:  Syed J Noor; Wei Tan; Gregory E Wilding; Laurie A Ford; Maurice Barcos; Sheila N J Sait; Annemarie W Block; James E Thompson; Eunice S Wang; Meir Wetzler
Journal:  Leuk Res       Date:  2010-08-19       Impact factor: 3.156

6.  Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.

Authors:  S Slot; K Smits; N W C J van de Donk; B I Witte; R Raymakers; J J W M Janssen; A E C Broers; P A W Te Boekhorst; S Zweegman
Journal:  Bone Marrow Transplant       Date:  2015-08-03       Impact factor: 5.483

7.  Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.

Authors:  Christina Hart; Sabine Klatt; Johann Barop; Gunnar Müller; Roland Schelker; Ernst Holler; Elisabeth Huber; Wolfgang Herr; Jochen Grassinger
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

8.  Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation.

Authors:  Juan Carlos Hernández-Boluda; Arturo Pereira; Nicolaus Kröger; Dietrich Beelen; Marie Robin; Martin Bornhäuser; Emanuele Angelucci; Antonin Vitek; Igor Wolfgang Blau; Riitta Niittyvuopio; Jürgen Finke; Jan J Cornelissen; Jakob Passweg; Peter Dreger; Eefke Petersen; Lothar Kanz; Jaime Sanz; Tsila Zuckerman; Nienke Zinger; Simona Iacobelli; Patrick Hayden; Tomasz Czerw; Donal McLornan; Ibrahim Yakoub-Agha
Journal:  Leukemia       Date:  2020-04-14       Impact factor: 11.528

Review 9.  Advances in myelofibrosis: a clinical case approach.

Authors:  John O Mascarenhas; Attilio Orazi; Kapil N Bhalla; Richard E Champlin; Claire Harrison; Ronald Hoffman
Journal:  Haematologica       Date:  2013-10       Impact factor: 9.941

Review 10.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.